EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Orion Pharma's Enterprise Value is BDT34,994 Mil.
Orion Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was BDT401 Mil. Therefore, Orion Pharma's EV-to-FCF for today is 87.31.
The historical rank and industry rank for Orion Pharma's EV-to-FCF or its related term are showing as below:
DHA:ORIONPHARM'
s EV-to-FCF Range Over the Past 10 Years
Min: -1383.78 Med: -15.66 Max: 409.69
Current: 87.48
During the past 12 years, the highest EV-to-FCF of Orion Pharma was 409.69. The lowest was -1383.78. And the median was -15.66.
DHA:ORIONPHARM's EV-to-FCF is ranked worse than 85.9% of 234
companies
in the Utilities - Independent Power Producers industry
Industry Median: 15.845
vs DHA:ORIONPHARM: 87.48
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Orion Pharma's PE Ratio (TTM) for today is calculated as:
Orion Pharma's share price for today is BDT28.50.
Orion Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-3.108.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Orion Pharma EV-to-FCF Related Terms
Orion Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Orion Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: EV-to-FCF Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma EV-to-FCF vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Orion Pharma's EV-to-FCF falls into.
Orion Pharma's current Enterprise Value is BDT34,994 Mil.
Orion Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT401 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a EV-to-FCF of 87.31 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #201 out of 234 companies in the Utilities - Independent Power Producers industry, placing it in the top 85.9%.
Is Orion Pharma's EV-to-FCF too high?
Orion Pharma's current EV-to-FCF is 87.31. The Utilities - Independent Power Producers industry median EV-to-FCF is 15.85. Orion Pharma's value of 87.31 is 451% above this industry median. Based on the distribution chart, Orion Pharma ranks #201 out of 234 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's EV-to-FCF compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #201 out of 234 companies for EV-to-FCF. This places Orion Pharma in the lower half of its industry. The industry median EV-to-FCF is 15.85. Orion Pharma's value of 87.31 is 451% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for an Utilities - Independent Power Producers company?
The median EV-to-FCF among Utilities - Independent Power Producers companies is 15.85, based on 234 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current EV-to-FCF of 87.31 is 451% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median EV-to-FCF is 15.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current EV-to-FCF is 87.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.38, compared to a current price of BDT28.50 — trading 39.8% above its estimated fair value. The current EV-to-FCF is 87.31 and 451% above the Utilities - Independent Power Producers industry median of 15.85. Orion Pharma's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current EV-to-FCF is 87.31 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.50 is trading 39.8% above its estimated GF Value™ of BDT20.38.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
EV-to-FCF: 87.31
GF Value™: BDT20.38 vs. price of BDT28.50 (39.8% above fair value)
Industry Position: 451% above the Utilities - Independent Power Producers median (#201 of 234)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
69GF Score
Get the complete analysis for DHA:ORIONPHARM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
